CoChat

Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer

Open access
Phillips, Therese, Simmons, Pauline, Inzunza, Hector D., Cogswell, John, Novotny, James, Taylor, Clive, Zhang, Xiaoling · 2015 · Applied Immunohistochemistry & Molecular Morphology

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune checkpoint inhibitor antibody, developed by Bristol-Myers Squibb Inc., has activity across non-small cell lung cancer (NSCLC) histologies and is Food and Drug Administration approved for treatment of metastatic squamous NSCLC with progression on or after platinum-based chemotherapy. PD-L1 has been investigated as a potential biomarker to predict clinical response to nivolumab in clinical settings. We report an automated PD-L1 immunohistochemistry (IHC) assay, which was developed to detect cell surface PD-L1 in formalin-fixed paraffin-embedded human tumor tissue specimens using Dako's Autostainer Link 48. The primary antibody for this assay is a rabbit monoclonal anti-human PD-L1 antibody, clone 28-8. The specificity of 28-8 for PD-L1 was demonstrated by antigen competition and genetic deletion of PD-L1 in tumor cell lines. The specificity of the PD-L1 IHC assay was further evaluated in a collection of 30 normal human tissues. The PD-L1 IHC assay was optimized for high sensitivity and precision in routine application. A pathology scoring and interpretation method specific to nivolumab clinical studies was adopted for the assay. The analytical performance of the assay was validated for application in the determination of PD-L1 status in human NSCLC specimens. The clinical application of the assay and scoring method was further validated in 3 Clinical Laboratory Improvement Amendments certified labs. The assay is currently being investigated in a variety of clinical studies for use as an in vitro diagnostic to select and stratify patients for treatment with the anti-PD-1 therapeutic antibody, nivolumab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/pai.0000000000000256

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Positive PD-L1 membrane staining in NSCLC tumor tissues illustrating intensity grades (top, ×20) and PD-L1 tumor scores (bottom, ×40). NSCLC indicates non–small cell lung cancer; PD-L1, programmed cell death 1 ligand 1.
FIGURE 1 Positive PD-L1 membrane staining in NSCLC tumor tissues illustrating intensity grades (top, ×20) and PD-L1 tumor scores (bottom, ×40). NSCLC indicates non–small cell lung cancer; PD-L1, programmed cell death 1 ligand 1.CC BY-NC-ND · PubMed Central
FIGURE 2 Photomicrographs (×40) of HT-29 parental and PD-L1 overexpressing FFPE cell pellets stained by the PD-L1 IHC assay with and without antigen competition. FFPE indicates formalin-fixed paraffin-embedded; IHC, immunohistochemistry; NCR, negative control reagent; PD-L1, programmed cell death 1 ligand 1.
FIGURE 2 Photomicrographs (×40) of HT-29 parental and PD-L1 overexpressing FFPE cell pellets stained by the PD-L1 IHC assay with and without antigen competition. FFPE indicates formalin-fixed paraffin-embedded; IHC, immunohistochemistry; NCR, negative control reagent; PD-L1, programmed cell death 1 ligand 1.CC BY-NC-ND · PubMed Central
FIGURE 3 Photomicrographs (×40) of parental and PD-L1 knock-out (KO)-stable FFPE cell pellets stained by the PD-L1 IHC assay. FFPE indicates formalin-fixed paraffin-embedded; IHC, immunohistochemistry; NCR, negative control reagent; PD-L1, programmed cell death 1 ligand 1.
FIGURE 3 Photomicrographs (×40) of parental and PD-L1 knock-out (KO)-stable FFPE cell pellets stained by the PD-L1 IHC assay. FFPE indicates formalin-fixed paraffin-embedded; IHC, immunohistochemistry; NCR, negative control reagent; PD-L1, programmed cell death 1 ligand 1.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 1

  1. Antonia SJ Grosso JF Horak CE Association of tumor pd-l1 expression and immune biomarkers with clinical activity in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. J Thoracic Oncology. 2013; 8(suppl 2): P907.

Cited by

See all 189

Metadata

Authors
Phillips, T., Simmons, P., Inzunza, H. D., Cogswell, J., Novotny, J., Taylor, C., & Zhang, X.
Affiliations
  • Bristol-Myers Squibb (United States) (US)
  • University of Southern California (US)
Corresponding author
  • Simmons, Pauline
  • Zhang, Xiaoling
Venue
Applied Immunohistochemistry & Molecular Morphology
Published
2015-09
Volume
23
Issue
8
Pages
541-549
ISSN
  • 1533-4058 (ISSN-L)
  • 1541-2016
OpenAlex
W1277869758
Cited by
189
References
18
Citations by year
2026: 6 · 2025: 5 · 2024: 8 · 2023: 10 · 2022: 10 · 2021: 21 · 2020: 21 · 2019: 32 · 2018: 20 · 2017: 28 · 2016: 27 · 2015: 1
FWCI
11.06
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Applied immunohistochemistry & molecular morphology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • National Cancer Institute
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
PD-L1 immunohistochemistry, non-small cell lung cancer, nivolumab, PD-1 inhibitors, antibody specificity, formalin-fixed paraffin-embedded tissue, predictive biomarkers, in vitro diagnostic assays, assay validation, immunotherapy selection
MeSH terms
Antibodies, Monoclonal, Automation, Carcinoma, Non-Small-Cell Lung, Humans, Immunohistochemistry, Lung Neoplasms, Cell Line, Tumor, Gene Knockdown Techniques, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. https://app.cochat.ai/papers/10.1097/pai.0000000000000256
The paper
Phillips, T., Simmons, P., Inzunza, H. D., Cogswell, J., Novotny, J., Taylor, C., & Zhang, X. (2015). Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Applied Immunohistochemistry & Molecular Morphology. https://doi.org/10.1097/pai.0000000000000256

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.